How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis
(2022)
Journal Article
Faria, R., Saramago, P., Cox, E., Weng, S., Iyen, B., Akyea, R. K., Humphries, S. E., Qureshi, N., & Woods, B. (2023). How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis. Atherosclerosis, 367, 40-47. https://doi.org/10.1016/j.atherosclerosis.2022.12.001
Background and aims
This study aimed to ascertain how the long-term benefits and costs of diagnosis and treatment of familial hypercholesterolaemia (FH) vary by prognostic factors and ‘cholesterol burden’, which is the effect of long-term exposure t...
Read More about How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis.